Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility
PR Newswire —
The $3.5 billion Lehigh Valley site will develop Lilly's next-generation weight-loss medicines, including retatrutide Company plans to create more than 2,800 manufacturing and construction jobs at Lilly's 10th U.S. manufacturing site announced since 2020 INDIANAPOLIS, Jan. 30, 2026...